Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine

C. Farsang, K. Kawecka-Jaszcz, J. Langan, F. Maritz, F. Zannad

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: This study aimed to compare the antihypertensive effect and tolerability of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor blocker with a dose-dependent and long-lasting antihypertensive effect, with that of amlodipine, a widely used long-acting dihydropyridine calcium antagonist, and with that of a combination of candesartan cilexetil and amlodipine. Design: Multicentre, randomised, double-blind, placebo-controlled parallel-group study. Setting: 42 general practice centres in France, Hungary, Poland, South Africa and the United Kingdom. Patients: 341 men and women, aged 21 to 81 years, with primary hypertension and a sitting diastolic blood pressure (DBP) of 95 to 114mm Hg. Interventions: After a 4-week placebo run-in period, patients were randomised to once-daily treatment with candesartan cilexetil 8mg (n = 85), amlodipine 5mg (n = 84), candesartan cilexetil 8mg plus amlodipine 5mg (n = 89), or placebo (n = 83) for 8 weeks. Main Outcome Measures: Differences between treatments in change in blood pressure from randomisation to the end of the study were evaluated using analysis of covariance. Results: All active treatment regimens resulted in marked reductions in sitting and standing blood pressures compared with placebo (p <0.001). Co-administration of candesartan cilexetil and amlodipine resulted in statistically significant and clinically important greater blood pressure reductions than either drug alone, with differences in adjusted mean systolic blood pressure (SBP)/DBP reductions of 5.6/2.0mm Hg (sitting) and 6.7/3.4mm Hg (standing) vs amlodipine; and of 5.8/0.8mm Hg (sitting) and 6.8/3.9mm Hg (standing) vs candesartan cilexetil (p <0.05 for combination therapy vs both monotherapies, except for sitting DBP; not significant). All treatments were well tolerated. Conclusions: This study not only confirms the efficacy and tolerability of candesartan cilexetil and amlodipine in patients with primary hypertension, but also shows that their combination results in a clinically important enhancement of antihypertensive effect while maintaining tolerability.

Original languageEnglish
Pages (from-to)17-23
Number of pages7
JournalClinical Drug Investigation
Volume21
Issue number1
Publication statusPublished - 2001

Fingerprint

Amlodipine
Antihypertensive Agents
Blood Pressure
Placebos
candesartan cilexetil
Hypertension
Angiotensin II Type 1 Receptor Blockers
Therapeutics
Hungary
Poland
Random Allocation
South Africa
General Practice
France
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. / Farsang, C.; Kawecka-Jaszcz, K.; Langan, J.; Maritz, F.; Zannad, F.

In: Clinical Drug Investigation, Vol. 21, No. 1, 2001, p. 17-23.

Research output: Contribution to journalArticle

Farsang, C. ; Kawecka-Jaszcz, K. ; Langan, J. ; Maritz, F. ; Zannad, F. / Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. In: Clinical Drug Investigation. 2001 ; Vol. 21, No. 1. pp. 17-23.
@article{7e974b5ef716437f96b11fb5598ba6e8,
title = "Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine",
abstract = "Objective: This study aimed to compare the antihypertensive effect and tolerability of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor blocker with a dose-dependent and long-lasting antihypertensive effect, with that of amlodipine, a widely used long-acting dihydropyridine calcium antagonist, and with that of a combination of candesartan cilexetil and amlodipine. Design: Multicentre, randomised, double-blind, placebo-controlled parallel-group study. Setting: 42 general practice centres in France, Hungary, Poland, South Africa and the United Kingdom. Patients: 341 men and women, aged 21 to 81 years, with primary hypertension and a sitting diastolic blood pressure (DBP) of 95 to 114mm Hg. Interventions: After a 4-week placebo run-in period, patients were randomised to once-daily treatment with candesartan cilexetil 8mg (n = 85), amlodipine 5mg (n = 84), candesartan cilexetil 8mg plus amlodipine 5mg (n = 89), or placebo (n = 83) for 8 weeks. Main Outcome Measures: Differences between treatments in change in blood pressure from randomisation to the end of the study were evaluated using analysis of covariance. Results: All active treatment regimens resulted in marked reductions in sitting and standing blood pressures compared with placebo (p <0.001). Co-administration of candesartan cilexetil and amlodipine resulted in statistically significant and clinically important greater blood pressure reductions than either drug alone, with differences in adjusted mean systolic blood pressure (SBP)/DBP reductions of 5.6/2.0mm Hg (sitting) and 6.7/3.4mm Hg (standing) vs amlodipine; and of 5.8/0.8mm Hg (sitting) and 6.8/3.9mm Hg (standing) vs candesartan cilexetil (p <0.05 for combination therapy vs both monotherapies, except for sitting DBP; not significant). All treatments were well tolerated. Conclusions: This study not only confirms the efficacy and tolerability of candesartan cilexetil and amlodipine in patients with primary hypertension, but also shows that their combination results in a clinically important enhancement of antihypertensive effect while maintaining tolerability.",
author = "C. Farsang and K. Kawecka-Jaszcz and J. Langan and F. Maritz and F. Zannad",
year = "2001",
language = "English",
volume = "21",
pages = "17--23",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine

AU - Farsang, C.

AU - Kawecka-Jaszcz, K.

AU - Langan, J.

AU - Maritz, F.

AU - Zannad, F.

PY - 2001

Y1 - 2001

N2 - Objective: This study aimed to compare the antihypertensive effect and tolerability of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor blocker with a dose-dependent and long-lasting antihypertensive effect, with that of amlodipine, a widely used long-acting dihydropyridine calcium antagonist, and with that of a combination of candesartan cilexetil and amlodipine. Design: Multicentre, randomised, double-blind, placebo-controlled parallel-group study. Setting: 42 general practice centres in France, Hungary, Poland, South Africa and the United Kingdom. Patients: 341 men and women, aged 21 to 81 years, with primary hypertension and a sitting diastolic blood pressure (DBP) of 95 to 114mm Hg. Interventions: After a 4-week placebo run-in period, patients were randomised to once-daily treatment with candesartan cilexetil 8mg (n = 85), amlodipine 5mg (n = 84), candesartan cilexetil 8mg plus amlodipine 5mg (n = 89), or placebo (n = 83) for 8 weeks. Main Outcome Measures: Differences between treatments in change in blood pressure from randomisation to the end of the study were evaluated using analysis of covariance. Results: All active treatment regimens resulted in marked reductions in sitting and standing blood pressures compared with placebo (p <0.001). Co-administration of candesartan cilexetil and amlodipine resulted in statistically significant and clinically important greater blood pressure reductions than either drug alone, with differences in adjusted mean systolic blood pressure (SBP)/DBP reductions of 5.6/2.0mm Hg (sitting) and 6.7/3.4mm Hg (standing) vs amlodipine; and of 5.8/0.8mm Hg (sitting) and 6.8/3.9mm Hg (standing) vs candesartan cilexetil (p <0.05 for combination therapy vs both monotherapies, except for sitting DBP; not significant). All treatments were well tolerated. Conclusions: This study not only confirms the efficacy and tolerability of candesartan cilexetil and amlodipine in patients with primary hypertension, but also shows that their combination results in a clinically important enhancement of antihypertensive effect while maintaining tolerability.

AB - Objective: This study aimed to compare the antihypertensive effect and tolerability of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor blocker with a dose-dependent and long-lasting antihypertensive effect, with that of amlodipine, a widely used long-acting dihydropyridine calcium antagonist, and with that of a combination of candesartan cilexetil and amlodipine. Design: Multicentre, randomised, double-blind, placebo-controlled parallel-group study. Setting: 42 general practice centres in France, Hungary, Poland, South Africa and the United Kingdom. Patients: 341 men and women, aged 21 to 81 years, with primary hypertension and a sitting diastolic blood pressure (DBP) of 95 to 114mm Hg. Interventions: After a 4-week placebo run-in period, patients were randomised to once-daily treatment with candesartan cilexetil 8mg (n = 85), amlodipine 5mg (n = 84), candesartan cilexetil 8mg plus amlodipine 5mg (n = 89), or placebo (n = 83) for 8 weeks. Main Outcome Measures: Differences between treatments in change in blood pressure from randomisation to the end of the study were evaluated using analysis of covariance. Results: All active treatment regimens resulted in marked reductions in sitting and standing blood pressures compared with placebo (p <0.001). Co-administration of candesartan cilexetil and amlodipine resulted in statistically significant and clinically important greater blood pressure reductions than either drug alone, with differences in adjusted mean systolic blood pressure (SBP)/DBP reductions of 5.6/2.0mm Hg (sitting) and 6.7/3.4mm Hg (standing) vs amlodipine; and of 5.8/0.8mm Hg (sitting) and 6.8/3.9mm Hg (standing) vs candesartan cilexetil (p <0.05 for combination therapy vs both monotherapies, except for sitting DBP; not significant). All treatments were well tolerated. Conclusions: This study not only confirms the efficacy and tolerability of candesartan cilexetil and amlodipine in patients with primary hypertension, but also shows that their combination results in a clinically important enhancement of antihypertensive effect while maintaining tolerability.

UR - http://www.scopus.com/inward/record.url?scp=0035146855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035146855&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 17

EP - 23

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 1

ER -